European Association for the Study of Diabetes
T2DM Hyperglycaemia 2022
This guideline holds 44 pages.
Summary
Joint ADA/EASD consensus prioritises cardiovascular risk, heart failure, and CKD as drivers of drug choice over glycaemic control alone. GLP-1 RAs and SGLT2-i move to second-line regardless of HbA1c when CV disease, HF or CKD is present. Personalised HbA1c targets 6.5–8.0% based on patient profile.
How the evidence was graded
Grading system
Class I–II
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- European Association for the Study of Diabetes
- Published
- 2022
- Region
- EU
- Language
- English
- Grading system
- Class I–II
Keywords
- Type 2 Diabetes
- GLP-1 RA
- SGLT2i
- Personalised targets
- CV risk
- HbA1c
More in endocrinology and metabolism
- Diabetic kidney disease (Update 2026) : Guidelines in a collaboration of the Austrian Diabetes Association and the Austrian Society of NephrologyAustrian Diabetes Association and Austrian Society of Nephrology · 2026
- Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of EndocrinologyWorld Health Organization · 2026
